Editorial Staff

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

/in , , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Threats to intellectual property, political pressure to lower prices, disruption of clinical trials will cause long-term harm

BOSTON – Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

“There will certainly be worldwide demand for COVID-19 treatments,” said William Smith, author of “The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector.”  “But they will also require massive investments in clinical development and manufacturing, and political pressure on pricing makes it impossible for companies to recoup those investments.”

Cipro is an antibiotic well-suited to treat anthrax, which began arriving in mailboxes in the weeks after September 11, 2001.  The Centers for Disease Control recommends that patients exposed to the bacteria take Cipro twice a day for 60 days.  Despite the fact that the entire course of treatment would only cost $219, Bayer agreed to cut the price in half after the U.S. Secretary of Health and Human Services at that time threatened to take away the company’s patent.

More recently, when Gilead announced it would invest $1 billion in Remdesivir, a promising COVID-19 treatment, one would have thought the company’s stock would rise.  Instead, it fell 5 percent.  A number of analysts remarked that the reason was fears that political pressure would result in very low prices or threats to Gilead’s patent.

Some investors and industry leaders may conclude that investments in major public health emergencies should be avoided in favor of research on lifestyle treatments or medications for less serious conditions that aren’t accompanied by threats to intellectual property or pressure to reduce prices.

Political pressure to cut prices is likely to be most acute in the area of vaccines, where the federal government is providing grants to companies such as Johnson & Johnson and Moderna.  Many policymakers will likely see any new vaccine that emerges from research that was partially funded by the government as public property.

“There may be humanitarian reasons why companies choose not to profit from their treatments,” said Pioneer Executive Director Jim Stergios.  “But policymakers should also be aware that threats to intellectual property create significant disincentives to investment.”

In 2018, Massachusetts institutions received nearly $3 billion in National Institutes of Health funding, the second highest amount among the states.  That same year, private venture companies invested $4.8 billion in the Commonwealth’s life sciences companies.  In terms of new businesses, more than a third of U.S.-based biotechs that went public in the first half of 2019 were Massachusetts-based.

These companies also face delays in clinical trials for non-COVID-19 treatments, which could significantly disrupt long-term product pipelines.  Since firms typically file patents before clinical trials begin, significant delays eat up the period during which treatments can be sold under patent before opening up to competition from generic makers.

The delays are particularly damaging to small firms, whose future may depend on a successful trial.

Smith’s recommendations include extending patent life on products by the period clinical trials were delayed by the pandemic, and that COVID-19 treatments in which companies made significant investments should be priced to allow a reasonable return on that investment.

About the Author

Dr. William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He writes about public policy issues impacting the life sciences industry with particular emphasis upon pharmaceuticals. Dr. Smith has 25 years of experience in government and in corporate roles. He spent ten years at Pfizer as Vice President of Public Affairs and Policy. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies, and was President of a small medical device company for three years. His career has also included senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Governor’s office in Massachusetts. He is affiliated as Research Fellow and Managing Director with the Center for the Study of Statesmanship at The Catholic University of America (CUA). He earned his PhD at CUA and a bachelor’s degree from Georgetown University.

About Pioneer

Mission
Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Vision
Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values
Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibility, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Content

American Federation for Children’s Tommy Schultz on School Choice & Edu Federalism

0 Comments
/
This week on “The Learning Curve," Gerard and Cara talk with Tommy Schultz, CEO-elect of the American Federation for Children (AFC). They discuss how COVID-19 school closures have increased the interest in alternatives to public schools, and what AFC's polling shows on shifts in attitudes toward school choice options in both urban and rural communities.

Key Madison Park Program Lags Other State Voc-Techs, but Shows Signs of Improvement

The co-operative education program at Boston’s Madison Park Technical Vocational High School, which places students in paid positions with local employers, lags far behind other Massachusetts vocational-technical schools in terms of both placements and number of employer contacts.  But with the school as a whole beginning to improve after years of turmoil, the co-op is also showing promising signs, according to a new study published by Pioneer Institute.

Ayaan Hirsi Ali, International Best-Selling Author & Human Rights Activist

0 Comments
/
This week on “The Learning Curve," Gerard and Cara talk with Ayaan Hirsi Ali, a Research Fellow at the Hoover Institution, founder of the AHA Foundation, and author of the books Prey: Immigration, Islam, and the Erosion of Women's Rights, Infidel: My Life, and Nomad: From Islam to America - A Personal Journey Through the Clash of Civilizations. 

Patient-centered Model Outshines Insurance-centered Healthcare during Pandemic

0 Comments
/
Joe Selvaggi talks with Pioneer Institute Senior Fellow Josh Archambault about his newest research paper entitled, "Direct Health Care Agreements: A New Option For Patient-Centered Care That Costs Less and Reduces Provider Burn-out" and how this emerging service model provided its patients with comprehensive health service throughout the COVID-19 pandemic.

WSJ Drama Editor Terry Teachout on Jazz Greats Louis Armstrong & Duke Ellington

This week on “The Learning Curve," Gerard and guest co-host Kerry McDonald continue our celebration of Black achievements with Terry Teachout, drama critic at The Wall Street Journal, and author of such books as Pops: A Life of Louis Armstrong and Duke: A Life of Duke Ellington.

Wealth Migration Trends: Remote Work Technology Empowers Workers to Live Anywhere

0 Comments
/
Host Joe Selvaggi talks with Pioneer Institute’s Andrew Mikula about his recent research into migration trends of high-income individuals, how pandemic-related technologies may accelerate that movement, and what challenges these changes present for policy makers.

UGA Prof. Valerie Boyd on Zora Neale Hurston, the Harlem Renaissance, & Black History Month

0 Comments
/
This week on “The Learning Curve," Cara and Gerard celebrate Black History Month with Professor Valerie Boyd, the Charlayne Hunter-Gault Distinguished Writer in Residence and Associate Professor of Journalism at the University of Georgia, and the definitive biographer of Zora Neale Hurston. Boyd discusses why Hurston is such an important novelist and cultural figure, and the influence of Hurston’s 1937 classic novel, Their Eyes Were Watching God, on American literature.

New Study Finds Pandemic-Spurred Technologies Lowered Barriers to Exit in High-Cost States

Both employers and households will find it easier to leave major job centers as technologies made commonplace by the COVID-19 pandemic have led to a rethinking of the geography of work, according to a new study published by Pioneer Institute.

Interstate Legal Skirmish: New Hampshire Takes Massachusetts Telecommuter Tax to the Supreme Court

0 Comments
/
Host Joe Selvaggi talks with legal scholar and George Mason University Law Professor Ilya Somin about the details, the merits, and the likely implications of the Supreme Court case, New Hampshire v. Massachusetts, on state taxation power, federalism, and the power to vote with one’s feet.

Boston Catholic Schools Supt. Tom Carroll on National Catholic Schools Week

0 Comments
/
This week on “The Learning Curve," Cara and Gerard celebrate National Catholic Schools Week with Tom Carroll, superintendent of schools for the Archdiocese of Boston. He shares his view of the value that Catholic schools add; the reasons for their success at improving student outcomes and creating a sense of community; and their commitment to serving children from underprivileged backgrounds, regardless of religious affiliation. 

Connecticut’s Painful Journey: Wealth Squandered, Lessons Learned, Promise Explored

0 Comments
/
Host Joe Selvaggi talks with Connecticut Business and Industry Association’s President and CEO, Chris DiPentima, about what policy makers can learn from Connecticut’s journey from the wealthiest state in the nation, to one with more than a decade of negative job growth.

New Study Shows Significant Wealth Migration from Massachusetts to Florida, New Hampshire

Over the last 25 years, Massachusetts has consistently lost taxable income, especially to Florida and New Hampshire, via out-migration of the wealthy, according to a new Pioneer Institute study. In “Do The Wealthy Migrate Away From High-Tax States? A Comparison of Adjusted Gross Income Changes in Massachusetts and Florida,” Pioneer Institute Research Director Greg Sullivan and Research Assistant Andrew Mikula draw on IRS data showing aggregate migration flows by amount of adjusted gross income (AGI). The data show a persistent trend of wealth leaving high-tax states for low-tax ones, especially in the Sun Belt.